drugset / Trial / NCT00865384

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions

NCT00865384

Phase 1 Completed 24 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the relative bioavailability of 15 mg Mirtazapine Tablets by Purepac Pharmaceutical Co with that of 15 mg REMERON® Tablets by Organon Inc. following a single oral dose (1 x 15 mg) in healthy adult volunteers under non-fasting conditions.

Timeline

Start
2001-09
Primary completion
2001-09
Completion
2001-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 15 mg Oral

Indications

No indication recorded.